Is bosutinib a targeted drug? Belong to several generations

Bosutinib (Bosutinib) is a 7-alkoxy-3-quinolinenitrile, a potent SRC and ABL tyrosine kinase inhibitor, suitable for chronic myelogenous leukemia (CML), especially Philadelphia chromosome-positive (Ph+) CML. As a result of reciprocal translocation, a BCR-ABL fusion protein is produced. The first BCR-ABL inhibitor, imatinib, was launched as a breakthrough in the management of chronic myelogenous leukemia; however, emerging resistance to imatinib poses a challenge for remission.

Bosutinib is a targeted drug that is a second-generationBCR-ABL inhibitor and a second-generation tyrosine kinase inhibitor (tyrosine kinase inhibitors, TKI), which inhibits most drug-resistant BCR-ABL mutations except V299L and T315, thus providing patients with more treatment options. Currently available clinical trials indicate that bosutinib is generally a safe and effective treatment option for patients with chronic myelogenous leukemia who have failed first-line TKIs and do not express the T315I mutation; however, for some patients, tolerability may be an issue.

The originator drug of bosutinib is not marketed in the country, so it cannot be included in medical insurance. Currently, the original drugs sold overseas include Turkish version and European version. The price of the Turkish version may be more than RMB 2,000 per box of 500mg*28, and the price of the European version may be more than RMB 30,000 (the price may fluctuate due to the exchange rate). There are also bosutinib generic drugs produced overseas in other countries. Their pharmaceutical ingredients are basically the same as those of the original drug. The price of 500mg*30 per box may be more than 2,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.